Cargando…

A case report of vaccine-induced immune thrombocytopenia and thrombosis syndrome after Ad26.COV2.S vaccine (Janssen/Johnson & Johnson)()

Detalles Bibliográficos
Autores principales:	Castan, Maxime, Damin-Pernik, Marlène, Thiéry, Guillaume, Page, Dominique, Smadja, David M., Bertoletti, Laurent
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. 2022
Materias:	Letter to Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8817724/ https://www.ncbi.nlm.nih.gov/pubmed/35135671 http://dx.doi.org/10.1016/j.therap.2022.01.014

Ejemplares similares

Impact of vaccine pause due to Thrombosis with thrombocytopenia syndrome (TTS) following vaccination with the Ad26.COV2.S vaccine manufactured by Janssen/Johnson & Johnson on vaccine hesitancy and acceptance among the unvaccinated population
por: Salmon, Daniel A., et al.
Publicado: (2022)

Janssen/Johnson & Johnson COVID-19 vaccine-related GBS in USA
Publicado: (2021)

Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine — United States, March–April 2021
por: Shay, David K., et al.
Publicado: (2021)

Widespread cutaneous reaction to the Johnson & Johnson Ad26.COV2.S vaccine
por: Sowell, Josiah, et al.
Publicado: (2021)

Reply to “Widespread Cutaneous Reaction to the Johnson & Johnson Ad26.Cov2.S Vaccine”
por: Malachowski, Stephen J., et al.
Publicado: (2022)

Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients — United States, April 2021
por: MacNeil, Jessica R., et al.
Publicado: (2021)

Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory Committee on Immunization Practices — United States, December 2021
por: Oliver, Sara E., et al.
Publicado: (2022)

Pulmonary embolism, transient ischaemic attack and thrombocytopenia after the Johnson & Johnson COVID-19 vaccine
por: Malik, Bilal, et al.
Publicado: (2021)

Severe Thrombocytopenia Two Weeks Following Immunization with the Janssen Ad26.CoV2.S Vaccine
por: Antonios, Bana, et al.
Publicado: (2022)

Vaccine-induced massive pulmonary embolism and thrombocytopenia following a single dose of Janssen Ad26.COV2.S vaccination
por: Curcio, Rosa, et al.
Publicado: (2022)

VITT REACTION ASSOCIATED WITH JOHNSON & JOHNSON COVID-19 VACCINE
por: AKUNA, MELANIE, et al.
Publicado: (2021)

Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021
por: Self, Wesley H., et al.
Publicado: (2021)

COVID-19 vaccination preferences during a pause in Johnson & Johnson vaccine administration
por: Wagner, Abram L., et al.
Publicado: (2023)

Johnson and Johnson COVID-19 Vaccination Triggering Pheochromocytoma Multisystem Crisis
por: Haji, Nahel, et al.
Publicado: (2021)

ANCA-associated vasculitis following Johnson and Johnson COVID-19 vaccine
por: Yadav, Rukesh, et al.
Publicado: (2022)

Transverse myelitis after Johnson & Johnson COVID-19 vaccine: illustrative case
por: Mathew, Ezek, et al.
Publicado: (2022)

Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults — VISION Network, 10 States, December 2021–March 2022
por: Natarajan, Karthik, et al.
Publicado: (2022)

A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson
por: Patel, Rikin, et al.
Publicado: (2022)

Evaluating Johnson and Johnson COVID-19 Vaccination Outcomes in a Low-Income Hispanic Population
por: Lamb, Christopher, et al.
Publicado: (2023)

M015 A PATIENT WITH AN ALLERGIC REACTION TO THE PFIZER COVID-19 VACCINE SUBSEQUENTLY TOLERATES JOHNSON&JOHNSON VACCINATION
por: Patterson, A., et al.
Publicado: (2021)

Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices — United States, July 2021
por: Rosenblum, Hannah G., et al.
Publicado: (2021)

Stevens-Johnson Syndrome Due to Influenza Vaccination
por: Tong, Jonathan, et al.
Publicado: (2020)

Neurologic Sequela of COVID-19: Guillain-Barré Syndrome Following Johnson & Johnson COVID-19 Vaccination
por: Carranza, Octavio, et al.
Publicado: (2022)

Cutaneous small vessel vasculitis following single-dose Janssen Ad26.COV2.S vaccination
por: Berry, Corbett T., et al.
Publicado: (2021)

Brève : Covid-19 : le vaccin Johnson & Johnson approuvé à l’unanimité par la FDA
por: Dalmat, Yann-Mickael
Publicado: (2021)

THE CLOT THICKENS: DOES THE JOHNSON & JOHNSON COVID-19 VACCINE INCREASE THE RISK OF THROMBUS IN A HYPERCOAGULABLE STATE?
por: RUTENBERG, DAVID, et al.
Publicado: (2021)

A Case Report of DVT following the Johnson and Johnson Vaccine against the Novel SARS-CoV-2
por: Bangolo, Ayrton, et al.
Publicado: (2022)

Acute Multiple Sclerosis Exacerbation After Vaccination With the Johnson & Johnson COVID-19 Vaccine: Novel Presentation and First Documented Case Report
por: Al-Midfai, Younus, et al.
Publicado: (2022)

Stevens‐Johnson Syndrome due to COVID‐19 vaccination
por: Mansouri, Parvin, et al.
Publicado: (2021)

Life of Johnson /
por: Boswell, James, 1740-1795
Publicado: (1980)

Philip Johnson
por: Jacobus, John M.
Publicado: (1962)

Mister Johnson /
por: Cary, Joyce, 1888-1957
Publicado: (1953)

Samuel Johnson /
por: Wain, John

Johnson’s Cyclopedia
Publicado: (1889)

337 Relapse of Membranous Nephropathy and Renal Sarcoidosis Following Exposure to SARS-CoV-2 Vaccine (Johnson & Johnson)
Publicado: (2022)

Understanding risk of thrombosis with thrombocytopenia syndrome after Ad26.COV2.S vaccination
por: Kulkarni, Prathit A., et al.
Publicado: (2021)

Tu1258: EFFECTIVENESS OF COVID-19 VIRAL VECTOR JANSSEN AD.26.COV2.S VACCINE AND COMPARISON WITH MRNA VACCINES IN CIRRHOSIS
por: John, Binu V., et al.
Publicado: (2022)

Sinopharm COVID-19 vaccine-induced Stevens–Johnson syndrome
por: Boualila, L., et al.
Publicado: (2022)

A Case Report of Acute Severe Necrotizing Pancreatitis following the Johnson & Johnson Vaccine against the Novel SARS-CoV-2
por: Bangolo, Ayrton I., et al.
Publicado: (2023)

The poems of Samuel Johnson
por: Johnson, Samuel, 1709-1784
Publicado: (1974)

Cannot write session to /tmp/vufind_sessions/sess_nem1odk8cdiprnuspl62039suo